HIGHLIGHTS
- who: Patrizia Malkomes from the Max Planck Institute for Heart and Lung Research, Department I Cardiac Development and Remodelling, Bad Nauheim, Germany have published the article: Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53, in the Journal: (JOURNAL)
- what: The authors demonstrate here that TGM2 is an essential survival factor in CRC highlighting the therapeutic potential of TGM2 inhibitors in CRC patients with high TGM2 expression. The authors demonstrate TGM2 as a suitable target molecule for future therapeutic interventions in CRC.
- how: The authors utilized the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.